Log in to search using one of your social media accounts:

 

Nationwide Children's gene therapy spinout raises $2.5M to test muscular dystrophy treatment
A gene therapy startup that spun out of Nationwide Children's Hospital six months ago has raised $2.5 million toward testing a treatment for a form of muscular dystrophy in patients. Myonexus Therapeutics Inc. is the fourth company to come out of gene therapy research at the Columbus hospital and the only one located in Central Ohio. CEO Michael Triplett and COO Bruce Halpryn are based in New Albany, and all of the contract research it sponsors takes place at Children's. “ The clinical impact… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 13, 2017 Category: Pharmaceuticals Authors: Carrie Ghose Source Type: news

Research reveals how diabetes in pregnancy affects baby ’s heart
Researchers at the  Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have discovered how high glucose levels — whether caused by diabetes or other factors — keep heart cells from maturing normally. Their findings help explain why babies born to women with diabetes are more likely to develop congenital heart disease.The study, which was led by Atsushi “Austin” Nakano, a UCLA associate professor of molecular, cell, and developmental biology and member of the Broad Stem Cell Research Center, was published today in the journal eLife.When developing heart cell...
Source: UCLA Newsroom: Health Sciences - December 12, 2017 Category: Universities & Medical Training Source Type: news

Voices: The Disabled Fl â neur
My diagnosis won ’ t keep me away from the city streets and the sweet energy that ’ s found there, even if someday I “ walk ” by dint of wheels. (Source: NYT Health)
Source: NYT Health - December 12, 2017 Category: Consumer Health News Authors: MARIAN RYAN Tags: Disabilities Muscular Dystrophy Wheelchairs Sidewalks Muscles Travel and Vacations Berlin (Germany) Source Type: news

SetPoint Medical wins FDA IDE trial nod for rheumatoid arthritis implant trial
SetPoint Medical said today it won FDA investigational device exemption clearance to launch a trial of its proprietary bioelectronic device designed to treat patients with drug refractory rheumatoid arthritis. The device is designed to be surgically placed on the vagus nerve to activate the body’s natural inflammatory reflex, the Valencia, Calif.-based company said. “We are ready to build on the published positive data from our earlier first-in-human proof-of-concept study of bioelectronic therapy in RA, which significantly improved measures of RA disease activity in this difficult-to-treat patient po...
Source: Mass Device - December 11, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Pain Management SetPoint Medical Source Type: news

Bilateral early activity in the hip flexors associated with falls in stroke survivors: preliminary evidence from laboratory-induced falls - Celinskis D, Grabiner MD, Honeycutt CF.
OBJECTIVE: Falls are the most common and expensive medical complication following stroke. Hypermetric reflexes have been suggested to impact post-stroke balance but no study has evaluated reflex amplitudes under real conditions of falls in this population.... (Source: SafetyLit)
Source: SafetyLit - December 11, 2017 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Pathophysiology of Reflex Syncope: A Review Pathophysiology of Reflex Syncope: A Review
This review elucidates the nomenclature and pathophysiology of various forms of reflex syncope, including vasovagal syncope, carotid sinus syndrome, and situational syncope.Journal of Cardiovascular Electrophysiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Lab notes: raise a glass to your ear and hail the dinosaur swan
It lived about 71m years ago, had a swan-like neck, razor-sharp “killer claws” and a duck-billed snout and was about the size of a mallard, with a long tail and longer legs. This ‘very weird’ creature (not my words, that’s an actual scientist’s description there) is apparently anew species of amphibious dinosaur, discovered in a smuggled fossil from Mongolia. And to toast that exciting news, you ’ll need a really good glass of champagne - but how will you know whether you’ve been passed plonk or premier cru?According to researchers, the sound of the bubbles reveals all ... As...
Source: Guardian Unlimited Science - December 8, 2017 Category: Science Authors: Tash Reith-Banks Tags: Science Source Type: news

In lab research, scientists slow progression of a fatal form of muscular dystrophy
(Saint Louis University) Saint Louis University researchers report that a new drug reduces fibrosis (scarring) and prevents loss of muscle function in an animal model of Duchenne muscular dystrophy (DMD). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 8, 2017 Category: International Medicine & Public Health Source Type: news

Adapted Crispr gene editing tool could treat incurable diseases, say scientists
New form of genetic engineering designed to boost gene activity could one day be used to overcome diseases such as diabetes and muscular dystrophyIncurable diseases such as diabetes and muscular dystrophy could be treated in future using a new form of genetic engineering designed to boost gene activity, according to scientists.The technique is an adapted version of the powerful gene editing tool called Crispr. While the original version of Crispr snips DNA in precise locations to delete faulty genes or over-write flaws in the genetic code, the modified form “turns up the volume” on selected genes.Continue readi...
Source: Guardian Unlimited Science - December 7, 2017 Category: Science Authors: Hannah Devlin Science correspondent Tags: Genetics Science Medical research Diabetes Biology Source Type: news

Researchers Advance Techniques To Change Gene Regulation And Treat Disease In Mice
Researchers were able to improve kidney function in mice with induced kidney damage, turn liver cells into insulin-producing pancreas cells in mice modeling type 1 diabetes, and improve muscle strength in animals with a muscular dystrophy-like condition. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 7, 2017 Category: Pharmaceuticals Authors: Ellie Kincaid, Forbes Staff Source Type: news

Dana-Farber Cancer Institute CEO Wants To Tax Biopharma To Pay For The NIH
We are all sympathetic with getting significantly more funding for the NIH. After all, this can benefit us all. Let ’s do so in a more creative fashion than levying a “tax”. Let’s try to find a win-win solution that we can all embrace. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 4, 2017 Category: Pharmaceuticals Authors: John LaMattina, Contributor Tags: NYSE:PFE NASDAQ:AAPL NYSE:MRK Source Type: news

Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002
Potential Registration Trial in Duchenne Muscular Dystrophy on Track to Initiate in First Quarter of 2018 Company to Host Conference Call and Webcast at 4:30 p.m. ET Today LOS ANGELES, Nov. 29, 2017 -- (Healthcare Sales & Marketing Network) -- Capri... Biopharmaceuticals, FDA Capricor Therapeutics, Duchenne muscular dystrophy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 29, 2017 Category: Pharmaceuticals Source Type: news

Three-camera setup to record simultaneously standardized high-definition video for smile analysis
ConclusionsThis new technique to capture standardized high-definition video and still images simultaneously from 3 positions is a reliable and practical tool. The technique is easy to learn and implement in the orthodontic office. (Source: Dental Technology Blog)
Source: Dental Technology Blog - November 27, 2017 Category: Dentistry Source Type: news

How soon will the 'ice apocalypse' come?
An emotive article on the ‘ice apocalypse’ by Eric Holthaus describes a terrifying vision of catastrophic sea level rise this century caused by climate change and the collapse of the Antarctic ice sheet. But how likely is this – and how soon could such a future be here?I ’ve been gripped by the story of Antarctic ‘ice cliff instability’ever since Rob DeConto and Dave Pollard published theircontroversial predictions last year. They suggesteddisintegration of ice shelves caused by global warming could leave behind coastal ice cliffs so tall they would be unstable, crumbling endlessly into ...
Source: Guardian Unlimited Science - November 23, 2017 Category: Science Authors: Tamsin Edwards Tags: Science Climate change Antarctica Source Type: news

United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca(R)
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2017 -- (Healthcare Sales & Marketing Network) -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivi... Biopharmaceuticals, FDA, Licensing United Therapeutics, Adcirca, tadalafil, Duchenne muscular dystrophy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 20, 2017 Category: Pharmaceuticals Source Type: news

Duchenne muscular dystrophy sufferers cannot walk
Brothers Elliot Johnson, 14, and Henry, 11, from Pennsylvania fear they won't be able to walk again after the FDA pulled the drugs that have kept their rare muscle disorder under control. (Source: the Mail online | Health)
Source: the Mail online | Health - November 17, 2017 Category: Consumer Health News Source Type: news

Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment
NEW YORK (Reuters) - Health insurer Anthem Inc has eased access to Sarepta Therapeutics' treatment for Duchenne muscular dystrophy, and on Thursday changed its reimbursement policy on its website to "medically necessary." (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Virtual gene editing startup to lease Cambridge lab after $40M round
The company, Exonics Therapeutics, said the Series A round will allow it to hire scientists to conduct preclinical research into a potential treatment for Duchenne muscular dystrophy. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 8, 2017 Category: American Health Authors: Max Stendahl Source Type: news

All babies in Europe should be screened for heart defects at birth
Only a few countries, including Poland, Ireland and Switzerland, currently recommend universal screening with pulse oximetry Related items fromOnMedica Blood test identifies high-risk lupus pregnancies Newborns screened for four additional genetic conditions Over 600,000 carry ‘sudden death’ gene fault The next generation of prenatal testing: let ’s proceed with caution Experts advise against screening for Duchenne Muscular Dystrophy (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 8, 2017 Category: UK Health Source Type: news

SLU researcher draws bulls eye around muscular dystrophy drug targets
(Saint Louis University) Scientist Francis M. Sverdrup, Ph.D., studies an inherited type of muscular dystrophy that typically begins with weakness in the face and shoulders before spreading to all skeletal muscles. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 7, 2017 Category: International Medicine & Public Health Source Type: news

Sarepta jumps into the CRISPR fray with Duke gene-editing pact
Cambridge-based Sarepta Therapeutics said Tuesday that it will seek to develop drugs for Duchenne muscular dystrophy using CRISPR/Cas9 gene-editing technology, jumping into an increasingly competitive but still uncertain field. Sarepta (Nasdaq: SRPT) said it had reached an agreement to exclusively license technology related to CRISPR/Cas9 from Duke University. Researchers there, led by Dr. Charles Gersbach, have shown that the technology can be used in mice to remove mutated parts of genes, or exons,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 31, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

Uncomfortable sight from an ancient reflex of the eye
(University of Pennsylvania School of Medicine) The eyes are for seeing, but they have other important biological functions, including automatic visual reflexes that go on without awareness. The reflexive system of the human eye also produces a conscious, visual experience, according to a new study from researchers in the Perelman School of Medicine and School of Arts and Sciences at the University of Pennsylvania. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 31, 2017 Category: International Medicine & Public Health Source Type: news

FDA declines to approve PTC's Duchenne drug
(Reuters) - The U.S. Food and Drug Administration has declined to approve PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, saying an additional clinical trial would be needed to prove the drug works. (Source: Reuters: Health)
Source: Reuters: Health - October 25, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA declines to approve PTC's Duchenne Muscular Dystrophy drug
(Reuters) - The U.S. Food and Drug Administration has declined to approve PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, saying an additional clinical trial would be needed to prove the drug works. (Source: Reuters: Health)
Source: Reuters: Health - October 25, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA rejects muscular dystrophy drug, says it doesn't work
U.S. regulators reject experimental drug for Duchenne muscular dystrophy. (Source: ABC News: Health)
Source: ABC News: Health - October 25, 2017 Category: Consumer Health News Tags: Health Source Type: news

Psychophysiology of proactive and reactive relational aggression - Murray-Close D, Holterman LA, Breslend NL, Sullivan A.
This study investigated the joint effects of parasympathetic and sympathetic nervous system reactivity to social and non-social stressors on proactive (i.e., goal-directed, unemotional) and reactive (i.e., emotional, impulsive) functions of relational aggr... (Source: SafetyLit)
Source: SafetyLit - October 24, 2017 Category: International Medicine & Public Health Tags: Violence and Weapons Issues Source Type: news

Mom-and-pop drug developers: How these parents are funding a drug for their sons
Both of their sons have a version of muscular dystrophy that has no approved treatment and is slowly robbing the boys of control over their hip and shoulder muscles. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 18, 2017 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

C-Path and CDISC announce therapeutic area user guide for duchenne muscular dystrophy
(Critical Path Institute (C-Path)) C-Path and CDISC announce the availability of TAUG-DMD v1.0: a therapeutic area user guide that describes the most common clinical concepts relevant to Duchenne studies using the CDISC standard format, which allows datasets from different sources to be compared or combined for analysis. Data covered include genetic information, cardiac and respiratory data, as well as results from specific measurements of strength and function. Data standards are also being developed for a variety of functional assessments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 18, 2017 Category: International Medicine & Public Health Source Type: news

Chronic inflammation may improve drug delivery in MD patients
Researchers at Children's National Health System found chronic inflammation is vital in sustained delivery of a new treatment for Duchenne muscular dystrophy. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 16, 2017 Category: Consumer Health News Source Type: news

Chronic inflammation may improve drug delivery in muscular dystrophy patients
Researchers at Children's National Health System found chronic inflammation is vital in sustained delivery of a new treatment for Duchenne muscular dystrophy. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 16, 2017 Category: Consumer Health News Source Type: news

Lasting bilateral mydriasis after traumatic brain injury may not always be a lost case - Athanasiou A, Balogiannis I, Magras I.
BACKGROUND: Lasting bilateral mydriasis and absence of pupillary light reflex following severe traumatic brain injury (TBI) are considered signs of irreversible brainstem damage and have been strongly associated with poor outcome. CASE DESCRIPTION: A young... (Source: SafetyLit)
Source: SafetyLit - October 16, 2017 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

What's the next step for exon skipping therapies to treat duchenne muscular dystrophy?
(Mary Ann Liebert, Inc./Genetic Engineering News) A team of leading European clinicians and scientists presents a unique perspective on how to move forward in the development of exon skipping therapies to treat the severe muscle-wasting disease Duchenne Muscular Dystrophy (DMD). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 16, 2017 Category: International Medicine & Public Health Source Type: news

Blink Reflex Recovery Cycle May Distinguish PSP From CBD Blink Reflex Recovery Cycle May Distinguish PSP From CBD
For indeterminate diagnoses, the R2 blink reflex recovery cycle can help distinguish between progressive supranuclear palsy and corticobasal degeneration, a study shows.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 12, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Brain-training games don ’t work
I heard an ad on the radio a few days ago… It was from one of those brain-training websites. It promised to boost your brainpower if you played their online games. When sites like this first came out a few years ago, I thought they would work. I even recommended them to my patients.    But it turns out these online brain-training games only train your brain in one thing… How to play their online games! That’s the conclusion of an extensive review by more than 70 scientists. They published the results of their research in the journal Psychological Science in the Public Interest.1 In fact, s...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

Capricor Therapeutics Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at World Muscle Society International Congress
Data Set the Stage for the Upcoming HOPE-2 Clinical Trial of CAP-1002 SAINT MALO, France, Oct. 4, 2017 -- (Healthcare Sales & Marketing Network) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), in its presentation today at the 22nd Annual International C... Regenerative Medicine Capricor Therapeutics, Duchenne muscular dystrophy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 4, 2017 Category: Pharmaceuticals Source Type: news

Thync touts first effective use of bioelectronics to treat psoriasis
Bioelectronics company Thync touted positive results today from the pilot study of its neuromodulation technology as a treatment for plaque psoriasis. The study showed that people using Thync’s technology experienced reduced redness, scaling and itchiness of their plaque psoriasis after four weeks, according to the Los Gatos, Calif.-based company. As part of the study, people used Thync’s neuromodulation technology for at least 10 minutes each day for four weeks. Both the treatment and control groups included people with mild to severe psoriasis, an autoimmune skin disorder without a cure or vaccine. ...
Source: Mass Device - October 4, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Neurological Neuromodulation/Neurostimulation Research & Development thync Source Type: news

There Are Better Ways to Mourn
On a crisp fall day in Vienna, Austria, I received a private tour of the crypt below Michaelerkirche (St. Michael’s Church). Bernard, the young Austrian man who led me down the steep stone staircase, had perfect English delivered in an inexplicably deep Southern accent. “Aye’ve been told my ax-sent is straynge be-fore,” he drawled, like a Confederate general. Bernard explained that during the Middle Ages, when the members of the Hapsburg court attended St. Michael’s, there was a cemetery located directly outside, in the courtyard. But, as so often happened in larger European cities, the cemete...
Source: TIME.com: Top Science and Health Stories - October 4, 2017 Category: Consumer Health News Authors: Caitlin Doughty Tags: Uncategorized Books Source Type: news

Armed with fresh trial data, Catabasis doubles down on Duchenne drug
Regrouping after a trial setback involving its lead drug for Duchenne muscular dystrophy, Cambridge-based Catabasis Pharmaceuticals is forging ahead with a late-stage study, touting new data on Wednesday hinting that the treatment can improve the lives of boys with the muscle-wasting disease. Catabasis (Nasdaq: CATB) previously announced in January that a Phase 2 study of the drug, called edasalonexent, had failed to meet its primary goal — significantly reducing leg muscle inflammation compared… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 4, 2017 Category: American Health Authors: Max Stendahl Source Type: news

A Late-Term Abortion Ban Passed By the House Faces Certain Defeat in the Senate
(WASHINGTON) — Most late-term abortions would be outlawed under legislation Republicans pushed through the House on Tuesday, a major priority of the GOP and conservative groups that won’t reach an eager President Donald Trump because it faces certain Senate defeat. The House approved the measure by a near party-line 237-189 vote. Though the bill’s fate is sealed, the push for abortion restrictions remains a touchstone issue for most Republicans, even as the party splinters between traditionalist conservatives and anti-establishment voters looking to roil Washington. Trump was ready to sign the measure, an...
Source: TIME.com: Top Science and Health Stories - October 4, 2017 Category: Consumer Health News Authors: Alan Fram / AP Tags: Uncategorized Congress onetime Reproductive Health Source Type: news

Something to Think About: Deeper values in daily activities
Dr. Amit Sood?says, "I need to connect my daily life with thoughtful practices that remind me of our sacredness." Dear friend, The sneeze is a useful reflex to rid your nose of irritants. Coordinated by a sneezing center in the lower part of the brain (also called the brainstem), sneezing involves elevation of the tongue [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 4, 2017 Category: Databases & Libraries Source Type: news

'CRISPR-Gold' fixes Duchenne muscular dystrophy mutation in mice
(University of California - Berkeley) Scientists at the University of California, Berkeley, have engineered a new way to deliver CRISPR-Cas9 gene-editing technology inside cells and have demonstrated in mice that the technology can repair the mutation that causes Duchenne muscular dystrophy, a severe muscle-wasting disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 3, 2017 Category: International Medicine & Public Health Source Type: news

Nonviral CRISPR Delivery a Success
Researchers use gold nanoparticles to deliver CRISPR-Cas9 and correct a point mutation in a mouse model of Duchenne muscular dystrophy. (Source: The Scientist)
Source: The Scientist - October 2, 2017 Category: Science Tags: Daily News Source Type: news

Pupillary light reflex is altered in adolescent depression - Mestanikova A, Ondrejka I, Mestanik M, Cesnekova D, Visnovcova Z, Bujnakova I, Oppa M, Calkovska A, Tonhajzerova I.
Major depressive disorder is associated with abnormal autonomic regulation which could be noninvasively studied using pupillometry. However, the studies in adolescent patients are rare. Therefore, we aimed to study the pupillary light reflex (PLR), which c... (Source: SafetyLit)
Source: SafetyLit - September 30, 2017 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Neil Gorsuch Is Already Acting Like He ’s Been on the Supreme Court for Years
In its new term beginning October 2, the Supreme Court will consider many pressing questions. Can a baker refuse to make a cake for a gay wedding? Can states redraw districts to help a political party? And, does Justice Neil Gorsuch talk too much? Gorsuch has proven himself to be a forceful and dynamic presence on the bench, a jurist who cements the Court’s conservative tilt, infuriates liberals—not least because of the circumstances by which he got there—and breaks custom with his uncommon assertiveness. Considering Gorsuch in his robes is to grapple with what legacy President Trump will leave on the hig...
Source: TIME.com: Top Science and Health Stories - September 29, 2017 Category: Consumer Health News Authors: Tessa Berenson Tags: Uncategorized justice Neil Gorsuch Supreme Court Source Type: news

PTC Therapeutics Duchenne drug may work, data inconclusive: FDA panel
(Reuters) - PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, a devastating degenerative disease that mostly affects young boys, may work but the company will need to do more work to prove it, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - September 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Ellen Pao Has Some Sage Advice for Dealing With Sexism
Ellen Pao made history when she sued her employer, the powerful Silicon Valley venture capital firm Kleiner Perkins, for discrimination in 2015. She accused the firm of blocking women and people of color from meetings, email discussions and networking events, and of cultivating a boys-club culture in the office, filled with racist and sexist language. She lost the case but broke open a conversation about the pernicious problems of sexism and racism in the tech industry. Pao went on to become the CEO of Reddit, where she banned revenge porn and harassment. Since leaving Reddit, Pao has gone on to found Project Include with ...
Source: TIME.com: Top Science and Health Stories - September 28, 2017 Category: Consumer Health News Authors: Eliana Dockterman Tags: Uncategorized sexism sexism in tech Silicon Valley Source Type: news

Books, Rats and Elegant Shoes
Three documentaries out now that deserve to be on your radar. IN THE STACKS With Ex Libris: New York Public Library, prolific 87-year-old filmmaker Frederick Wiseman trains his ultra-perceptive lens on the NYPL system, an organism that makes New Yorkers’ lives better in ways big and small. OF RATS AND MEN The rat-phobic may shy away. But Theo Anthony’s Rat Film is as much about a city–specifically, Baltimore–as it is about rodents. It’s a sympathetic, if sometimes disturbing, look at how rats and humans get along. Or don’t. THE ART OF THE HEEL Michael Roberts’ Manolo: The Boy Who M...
Source: TIME.com: Top Science and Health Stories - September 28, 2017 Category: Consumer Health News Authors: Stephanie Zacharek Tags: Uncategorized documentaries Source Type: news

Promised Land
In the summer of 2015, a curious piece of world news brought a flicker of hope to the wretched Syrian city of Palmyra. Islamic State fighters had taken over the ancient town, toppling its monuments and executing anyone who resisted their draconian rules. And yet at one of the city’s darkest moments, rumors of a sanctuary far away began to filter in, generating dreams among a populace that had already lost everything. On Aug. 31 of that year, German Chancellor Angela Merkel declared that her country was prepared to take in hundreds of thousands of refugees fleeing war in the Middle East. “We can do this,” ...
Source: TIME.com: Top Science and Health Stories - September 28, 2017 Category: Consumer Health News Authors: Aryn Baker / Berlin Tags: Uncategorized finding home Germany Refugees Source Type: news

FDA pours cold water on PTC Therapeutics' Duchenne drug application
(Reuters) - PTC Therapeutics Inc has not supplied "persuasive" evidence that its experimental drug to treat a form of Duchenne muscular dystrophy is effective, a preliminary review by scientists at the U.S. Food and Drug Administration concluded. (Source: Reuters: Health)
Source: Reuters: Health - September 26, 2017 Category: Consumer Health News Tags: healthNews Source Type: news